NextGen Day

The use of the oral pill molnupiravir as a prophylactic to prevent an exposed person from getting the coronavirus disease is now being studied in clinical studies (Covid-19).

Dr. Benjamin Co, the clinical investigator for the MOVe-Ahead clinical trial at the Asian Hospital and Medical Center (AHMC), said the investigations have been ongoing since November last year at the AHMC in Alabang, Muntinlupa, and Quirino Memorial Medical Center in Project 4, Quezon City.

“Ang clinical trial na ginagawa natin ngayon ay sa bagong indikasyon. It has not been proven na puwede natin gamitin ito for post-exposure prophylaxis at ito po ang tinitignan natin ngayon puwede bang magamit (The clinical study that we are conducting is for a new indication. It has not been proven yet that we can use this for post-exposure prophylaxis and this is what we’re studying right now),” he said in a Laging Handa briefing Saturday.

The goal of the experiment, according to Co, is to discover if molnupiravir can be taken by someone who has been exposed to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).

“Ang ibig sabihin ng post-exposure prophylaxis ay kung kunwari ako, mayroon akong Covid at na-expose po kayo sa akin, ay maaari na ba kayong uminom ng molnupiravir para hindi kayo magkaroon ng infection,” he said.

Those interested in participating in the trials should call 0968-5583091 or 0927-0076642, according to Co.

MOVe-Ahead is a Phase 3 trial that will enroll roughly 1,332 people in 17 countries and give them either molnupiravir (800 mg) or placebo every 12 hours for five days.

Participants must be at least 18 years old and live in the same household as a Covid-19 patient to be eligible.

They must also have never had a Covid-19 vaccine and have never been infected with SARS-CoV-2.

“We will contact you during the clinical trial if you meet the inclusion requirements, and we will randomize you. We’ll start by obtaining your agreement to engage in this clinical trial and makatulong po tayong lahat sa world (that you wish to participate in this clinical trial) “Co remarked.

“Ang gusto nating malaman ngayon is makakalabas ba tayo sa pandemyang ito, and we can see if there is a medicine that can assist prevent us from, iyong ‘pag na-expose ka naman, iinom ka ng gamot para hindi ka na magkakaroon ng Covid,” he added.

All volunteers would be treated with care, and safety and follow-up measures would be in place, according to Co.

Molnupiravir was found to minimize the risk of hospitalization or death by around half in the first research.

Save/Share this story with QR CODE

---

Disclaimer

This article is for informational purposes only and does not constitute endorsement of any specific technologies or methodologies and financial advice or endorsement of any specific products or services.

Need to get in touch?

Feel free to Contact NextGenDay.com for comments, suggestions, reviews, or anything else.

---

We appreciate your reading. Simple Ways To Say Thanks & Support Us:
1.) GIVE A TIP. Send a small donation thru Paypal
Your DONATION will be used to fund and maintain NEXTGENDAY.com
Subscribers in the Philippines can make donations to mobile number 0917 906 3081, thru GCash.
3.) BUY or SIGN UP to our AFFILIATE PARTNERS.
4.) Give this news article a THUMBS UP, and Leave a Comment (at Least Five Words).

---

AFFILIATE PARTNERS

World Class Nutritional Supplements - Buy Highest Quality Products, Purest Most Healthy Ingredients, Direct to your Door! Up to 90% OFF.
Join LiveGood Today - A company created to satisfy the world's most demanding leaders and entrepreneurs, with the best compensation plan today.

---